Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience.
| Publicado en: | Journal of Clinical Oncology Vol. 41; pp. 9572 - 9573 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2023 Supplement 16
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=164015232&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 164015232 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2023 Supplement 16 vid: 41 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 164015232 10.1200/JCO.2023.41.16_suppl.9572 164015232 ppf: 9572 ppct: 1 formats: tig: atl: Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience. aug: au: Rhea, Logan Daniels, Megan Sabo, Roy Poklepovic, Andrew Stewart affil: Virginia Commonwealth University Health System, Richmond, VA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|